325 related articles for article (PubMed ID: 19723512)
1. Antroquinonol displays anticancer potential against human hepatocellular carcinoma cells: a crucial role of AMPK and mTOR pathways.
Chiang PC; Lin SC; Pan SL; Kuo CH; Tsai IL; Kuo MT; Wen WC; Chen P; Guh JH
Biochem Pharmacol; 2010 Jan; 79(2):162-71. PubMed ID: 19723512
[TBL] [Abstract][Full Text] [Related]
2. Methoxychalcone induces cell-cycle arrest and apoptosis in human hormone-resistant prostate cancer cells through PI 3-kinase-independent inhibition of mTOR pathways.
Sun YW; Huang WJ; Hsiao CJ; Chen YC; Lu PH; Guh JH
Prostate; 2010 Sep; 70(12):1295-306. PubMed ID: 20623631
[TBL] [Abstract][Full Text] [Related]
3. Antroquinonol, a natural ubiquinone derivative, induces a cross talk between apoptosis, autophagy and senescence in human pancreatic carcinoma cells.
Yu CC; Chiang PC; Lu PH; Kuo MT; Wen WC; Chen P; Guh JH
J Nutr Biochem; 2012 Aug; 23(8):900-7. PubMed ID: 21840189
[TBL] [Abstract][Full Text] [Related]
4. Antroquinonol inhibits NSCLC proliferation by altering PI3K/mTOR proteins and miRNA expression profiles.
Kumar VB; Yuan TC; Liou JW; Yang CJ; Sung PJ; Weng CF
Mutat Res; 2011 Feb; 707(1-2):42-52. PubMed ID: 21185843
[TBL] [Abstract][Full Text] [Related]
5. Silibinin efficacy against human hepatocellular carcinoma.
Varghese L; Agarwal C; Tyagi A; Singh RP; Agarwal R
Clin Cancer Res; 2005 Dec; 11(23):8441-8. PubMed ID: 16322307
[TBL] [Abstract][Full Text] [Related]
6. EGCG inhibits protein synthesis, lipogenesis, and cell cycle progression through activation of AMPK in p53 positive and negative human hepatoma cells.
Huang CH; Tsai SJ; Wang YJ; Pan MH; Kao JY; Way TD
Mol Nutr Food Res; 2009 Sep; 53(9):1156-65. PubMed ID: 19662644
[TBL] [Abstract][Full Text] [Related]
7. mTOR and P70 S6 kinase expression in primary liver neoplasms.
Sahin F; Kannangai R; Adegbola O; Wang J; Su G; Torbenson M
Clin Cancer Res; 2004 Dec; 10(24):8421-5. PubMed ID: 15623621
[TBL] [Abstract][Full Text] [Related]
8. A unique P-glycoprotein interacting agent displays anticancer activity against hepatocellular carcinoma through inhibition of GRP78 and mTOR pathways.
Kuo TC; Chiang PC; Yu CC; Nakagawa-Goto K; Bastow KF; Lee KH; Guh JH
Biochem Pharmacol; 2011 May; 81(9):1136-44. PubMed ID: 21371443
[TBL] [Abstract][Full Text] [Related]
9. Reexpression of ARHI inhibits tumor growth and angiogenesis and impairs the mTOR/VEGF pathway in hepatocellular carcinoma.
Zhao X; Li J; Zhuo J; Cai L
Biochem Biophys Res Commun; 2010 Dec; 403(3-4):417-21. PubMed ID: 21093415
[TBL] [Abstract][Full Text] [Related]
10. Ganoderiol F, a ganoderma triterpene, induces senescence in hepatoma HepG2 cells.
Chang UM; Li CH; Lin LI; Huang CP; Kan LS; Lin SB
Life Sci; 2006 Aug; 79(12):1129-39. PubMed ID: 16635496
[TBL] [Abstract][Full Text] [Related]
11. Modulation of the activities of AMP-activated protein kinase, protein kinase B, and mammalian target of rapamycin by limiting energy availability with 2-deoxyglucose.
Jiang W; Zhu Z; Thompson HJ
Mol Carcinog; 2008 Aug; 47(8):616-28. PubMed ID: 18247380
[TBL] [Abstract][Full Text] [Related]
12. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells.
Dowling RJ; Zakikhani M; Fantus IG; Pollak M; Sonenberg N
Cancer Res; 2007 Nov; 67(22):10804-12. PubMed ID: 18006825
[TBL] [Abstract][Full Text] [Related]
13. mTOR, AMPK, and GCN2 coordinate the adaptation of hepatic energy metabolic pathways in response to protein intake in the rat.
Chotechuang N; Azzout-Marniche D; Bos C; Chaumontet C; Gausserès N; Steiler T; Gaudichon C; Tomé D
Am J Physiol Endocrinol Metab; 2009 Dec; 297(6):E1313-23. PubMed ID: 19738034
[TBL] [Abstract][Full Text] [Related]
14. KLF6 transcription factor protects hepatocellular carcinoma-derived cells from apoptosis.
Sirach E; Bureau C; Péron JM; Pradayrol L; Vinel JP; Buscail L; Cordelier P
Cell Death Differ; 2007 Jun; 14(6):1202-10. PubMed ID: 17347668
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of the HGF/MET autocrine loop induced by celecoxib and mediated by P-gp in MDR-positive human hepatocellular carcinoma cell line.
Mazzanti R; Platini F; Bottini C; Fantappiè O; Solazzo M; Tessitore L
Biochem Pharmacol; 2009 Jul; 78(1):21-32. PubMed ID: 19447220
[TBL] [Abstract][Full Text] [Related]
16. Serum response factor depletion affects the proliferation of the hepatocellular carcinoma cells HepG2 and JHH6.
Farra R; Dapas B; Pozzato G; Giansante C; Heidenreich O; Uxa L; Zennaro C; Guarnieri G; Grassi G
Biochimie; 2010 May; 92(5):455-63. PubMed ID: 20144681
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways.
Gazitt Y; Kolaparthi V; Moncada K; Thomas C; Freeman J
Int J Oncol; 2009 Feb; 34(2):551-61. PubMed ID: 19148492
[TBL] [Abstract][Full Text] [Related]
18. Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma.
Hui IC; Tung EK; Sze KM; Ching YP; Ng IO
Liver Int; 2010 Jan; 30(1):65-75. PubMed ID: 19845851
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effects of vitamins K1, K2 and K3 on hepatocellular carcinoma in vitro and in vivo.
Hitomi M; Yokoyama F; Kita Y; Nonomura T; Masaki T; Yoshiji H; Inoue H; Kinekawa F; Kurokohchi K; Uchida N; Watanabe S; Kuriyama S
Int J Oncol; 2005 Mar; 26(3):713-20. PubMed ID: 15703828
[TBL] [Abstract][Full Text] [Related]
20. Jak inhibitor induces S phase cell-cycle arrest and augments TRAIL-induced apoptosis in human hepatocellular carcinoma cells.
Fuke H; Shiraki K; Sugimoto K; Tanaka J; Beppu T; Yoneda K; Yamamoto N; Ito K; Masuya M; Takei Y
Biochem Biophys Res Commun; 2007 Nov; 363(3):738-44. PubMed ID: 17904524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
